Dackus et al. have recently published that aromatase inhibitors (AIs) (with or without ovarian ablation) were associated with better RFS and OS outcomes in ER+/HER2+ perimenopausal (aged 45–55 years) breast cancer patients, using data from the NCR [31]. Here, ERBB2 is linked to breast cancer.